While the association between non-steroidal anti-inflammatory drugs (NSAIDs) and upper gastrointestinal bleeding or perforation is accepted, the same cannot be said for the lower gastrointestinal tract'. We present a patient with rheumatoid arthritis where lower gastrointestinal tract problems developed following ingestion of piroxicam, an NSAID.
Case report
Mrs ME, a 67-year-old woman was admitted in November 1987 with rectal bleeding. She had severe rheumatoid arthritis and had been on steroids since 1974. In 1979, she had a partial gastrectomy for duodenal ulcer. In 1983, adhesions were divided for intestinal obstruction. In 1984, a spontaneous terminal ileal perforation was oversewn. Her medications are listed in Table 1 . She was pale with a pulse rate of 120 beats per minute and a systolic blood pressure of 80 mmHg. There were no abdominal signs. Rectal examination and sigmoidoscopy revealed dark red blood.
Her haemoglobin concentration was 8.8 g/dl, platelet count 488x1O9/l, and a clotting screen was normal. She was resuscitated. Gastroscopy failed to show any significant lesion. A radionuclide-labelled red blood cell scan localized the source of bleeding to the ileocaecal region ( Figure 1 ).
A right hemicolectomy was carried out. Four days later, her abdomen distended and she became unwell. A small bowel perforation 10 cm proximal to the anastomosis was oversewn. Six days later she rebled. Distal ileum was resected and a terminal ileostomy and colonic mucous fistula were fashioned. Already very ill, she started to bleed massively from her bladder. Cystoscopy showed gross haemorrhagic cystitis which was impossible to control with diathermy. Four units 
Discussion
Bleeding was localized to the ileocaecal region preoperatively ( Figure 1 ). The gross pathological specimen showed multiple shallow mucosal ulcers (Figure 2 ) throughout the ileum, caecum and ascending colon. Histological examination had excluded angiodysplasia or vasculitis, making these ulcers the most likely source of haemorrhage. In 1984, when admitted with a terminal ileal perforation and again prior to this admission, she had started oral piroxicam 3 weeks earlier. These events, both following a short period of piroxicam, suggest that the drug is likely to be the cause. A literature search provides supporting evidence. Rampton's review2 detailed case reports of small bowel ulcers, perforations, bleeding, strictures and reperforations following ingestion of NSAIDs. It is also noted that infants treated with indomethacin for patent ductus arteriosus have an increased incidence of-perforation and necrotizing enterocolitis2. A large epidemiological study found that patients taking NSAIDs had a 2.6 times increased risk of perforation and haemorrhage3. Studies'5 had shown that subjects taking NSAIDs, whether healthy volunteers or patients with rheumatoid or osteoarthritis, have increased intestinal permeability to 51Cr EDTA. Indomethacin suppositories had a similar effect, suggesting a systemic action. '11Indium labelled leucocyte scintigrams showed there was 'intestinal inflammation' with concomitant increased faecal excretion of the isotope. The main site affected is the small bowel. Radiological contrast studies in some patients demonstrated small bowel ulceration and strictures5.
Similar small bowel mucosal ulcers have been reported in patients with gastrointestinal bleeding6 but we have failed to find similar cases with perforations. However, rats given indomethacin developed similar ulcers in the distal small bowel7, some of which went on to perforation. It might be revealing to examine the distal small bowel ofNSAIDs users endoscopically.
As regards ill patients with haemorrhagic cystitis, bladder irrigation with 1% alum solution is worth trying8. There is no doubt that this saved our patient's life.
Baclofen (Lioresal) is frequently used in the treatment of spasticity. It acts principally at a spinal level to reduce muscle tone'. Gamma aminobutyric acid (GABA) agonists are generally thought to be antiepileptic, although manufacturers recommend caution in using baclofen in patients with known epilepsy and also avoiding abrupt withdrawal2. Epilepsy has been reported 7 h after baclofen overdosagel. This is the first reported case of status epilepticus caused by therapeutic doses of baclofen in a patient previously free of epilepsy.
Case report
A 35-year-old woman was admitted via the accident and emergency department in May 1987. She had been born prematurely in 1952 and had received high concentrations of oxygen which produced retrolental fibroplasia. In February 1984 she was prescribed baclofen for leg 'stiffness' thought to be secondary to birth injury. Examination then revealed increased resistance to passive movement although power, tendon reflexes and plantar responses were normal. She had occasional jerking movements ofher legs soon after bginning baclofen but an electroencephalogram (EEG) in May 1984 was normal. The baclofen was slowly increased to 80 mg a day. Between mid 1986 and early 1987 she had four episodes of loss of consciousness and was admitted to a different hospital where she was noted to have nocturnal fits with associated raised serum prolactin and an abnormal EEG. She was prescribed phenytoin and the baclofen was continued.
In May 1987 when admitted under our care she had had three fits in 24 h and then developed status epilepticus. Her condition deteriorated and she had more than 200 fits in two weeks and required assisted respiration. During her admission the baclofen was slowly reduced over a period of 3 weeks and the fits were controlled with phenytoin and sodium valproate. Her brain CT scan was normal. From July 1987 the anticonvulsant drugs were gradually reduced so that by July 1988 she was taking no medication. She was still free of fits when last seen in March 1989.
Discussion
The evidence is strong that baclofen was an important and probably the only factor precipitating her fits. It is unlikely that she had a tendency to epilepsy related to a brain injury at birth as her EEGs were normal when she was taking a small dose ofbaclofen and when off all medication. She never had convulsions when not taking baclofen. Fits can be caused by rapid withdrawal of baclofen3, especially in patients known to be liable to epilepsy, although it has not been shown to have a deleterious effect in patients with epilepsy4.
Baclofen is structurally similar to the inhibitory neurotransmitter, GABA, and stimulates GABA receptors. GABAergic mechanisms are important in the pathogenesis of epilepsy5. There are two types of GABA receptor, A and B, both of which are found both pre and post-synaptically. Stimulation of GABA-A receptors causes an influx ofchloride ions which has the effect of inhibiting plarizion, stabilizin the membrane and hence reducing the chance of epilepsy. Baclofen acting on GABA-B receptors hyperpolarizes neurons, by increasing K+ conductance6. Baclofen also decreas Ca2e conductance and thereby diminishes synaptic release ofsome neurotranamitters. How these effects relate to a proconvulsive action of baclofen is not yet clear.
It is suggested that baclofen can cause epilepsy and should be withdrawn gradually from all patients who develop epilepsy while taking it. 0141-0768/90/ 020115-02/402.00/0 © 1990 The Royal Society of Medicine
